Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Neoplasm
ADR ID BADD_A03004
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.16      Miscellaneous and site unspecified neoplasms malignant and unspecified
16.16.02      Neoplasms unspecified malignancy and site unspecified NEC
16.16.02.001      Neoplasm
Description New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. [MeSH]
MedDRA Code 10028980
MeSH ID D009369; D002277
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Cystoma | Epithelioma | Neoplasm | Neoplasm growth accelerated | Neoplasm NOS | Neoplasm of uncertain behavior of endocrine glands and nervous system | Neoplasm of uncertain behavior of other and unspecified sites and tissues | Neoplasm of uncertain behavior of other specified sites | Neoplasm of uncertain behavior, site unspecified | Neoplasm of uncertain behaviour of endocrine glands and nervous system | Neoplasm of uncertain behaviour of other and unspecified sites and tissues | Neoplasm of uncertain behaviour of other specified sites | Neoplasm of uncertain behaviour, site unspecified | Neoplasm of unspecified nature of bone, soft tissue, and skin | Neoplasm of unspecified nature of endocrine glands and other parts of nervous system | Neoplasm of unspecified nature of other specified sites | Neoplasm of unspecified nature, site unspecified | Neoplasms of unspecified nature | Neoplasm (NOS) | Solid tumour | Solid tumor | Tumour | Tumor | Hypervascular tumor | Hypervascular tumour | Neoplasms | Neoplasia | Neoplasias | Tumors | Cancer | Cancers | Malignancy | Malignancies | Malignant Neoplasms | Malignant Neoplasm | Neoplasm, Malignant | Neoplasms, Malignant | Benign Neoplasms | Neoplasms, Benign | Benign Neoplasm | Neoplasm, Benign
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00371Carmustine0.000224%
BADD_D00376Caspofungin--
BADD_D00410Celecoxib0.000134%
BADD_D00414Ceritinib0.001343%
BADD_D00424Cevimeline--
BADD_D00429Chlorambucil--
BADD_D00475Citalopram--
BADD_D00479Cladribine0.000153%
BADD_D00480Clarithromycin--
BADD_D00495Clofarabine--
BADD_D00497Clomiphene--
BADD_D00511Clozapine--
BADD_D00549Cyclophosphamide--
BADD_D00551Cyclosporine0.000111%
BADD_D00555Cyproterone acetate--
BADD_D00563Dabigatran0.002324%
BADD_D00564Dabigatran etexilate--
BADD_D00566Dabrafenib0.000246%
BADD_D00578Dapagliflozin--
BADD_D00586Darunavir--
BADD_D00589Dasatinib--
BADD_D00594Deferasirox0.002478%
BADD_D00615Desloratadine--
BADD_D00618Desogestrel--
BADD_D00648Diazepam0.000076%
BADD_D00699Docetaxel--
BADD_D00720Doxepin--
BADD_D00723Doxorubicin0.000336%
BADD_D00734Duloxetine0.000040%
BADD_D00736Dutasteride--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 9 Pages
ADReCS-Target
ADR Term Drug Name Target